EuroSIDA Newsletter

April 2016

ANNOUNCEMENTS

Dear EuroSIDA Study Investigators,

The staff at the EuroSIDA coordinating centre sends you many spring greetings and we kindly once again thank you for your continued excellent work and contribution to the EuroSIDA study.

As mentioned in the previous newsletter, 2015 was the last year where the EuroSIDA Study under the umbrella of EuroCoord, was funded by the EU. We are therefore in the process of evaluating the future structure for EuroSIDA data collection. This involves developing a simplified follow-form which will hopefully lessen the workload for our collaborating centres.
For this reason, **the next EuroSIDA dataset, planned for June, is postponed until autumn 2016.** As soon as the exact date has been decided, we will inform you. We apologize for any inconvenience and do let us know if you have any questions.

Dataset 43

We are very happy at the EuroSIDA coordinating centre, to receive a record high return of FU-forms in dataset 43. Approximately 12,500 forms were completed from 93 centres across Europe, Israel and Latin America. We thank all of you for your excellent work!
More than 15,000 patients are currently under active follow-up in EuroSIDA and more than 22,000 patients have been included in the study to date, ensuring EuroSIDA at the forefront of investigating long-term clinical prognosis for the general population of HIV-infected patients.

DAD funding ends

As previously announced, the DAD Oversight Committee has decided **not to continue funding of DAD** after the end of the current funding period, by completion of merger 17.
All events should still be reported to EuroSIDA via REDCap as they are currently, but D:A:D event forms should no longer be completed after 1 February 2016. DAD event forms requested by CHIP during the query process and during monitor visits **will be reimbursed**.

Enrolment status for the new EuroSIDA cohort

Enrolment in cohort 10 still continues for those sites that have not yet met their targets. Almost 4,000 patients have been enrolled in cohort 10, ensuring that EuroSIDA is at the forefront of investigating the uptake and outcome of treatment with the direct acting antivirals against hepatitis C. If your center has not yet met the original target, but you still have HIV-positive patients with positive HCV-antibody status not enrolled in EuroSIDA already, please continue to enroll patients.

Dataset 44

The schedule for Dataset 44 will be announced as soon as possible. Please wait for further developments.

EuroSIDA monitoring 2016

The 2016 monitoring season has begun. We look forward to meeting you at the sites!

REDCap

We have had a number of questions from investigators concerning how to enter the REDCap system. Please be aware that CHIP is working with more than one REDCap system and for EuroSIDA the link to be used is THIS.

New INSTI hypersensitivity sub-study nested in EuroSIDA

The new substudy looking at integrase inhibitor hypersensitivity and liver toxicity is now integrated in EuroSIDA and REDCap. Please fill out this form in connection with prospective follow-up in REDCap if asked to do so in the follow-up form. You can find the case definitions under EuroSIDA study documents HERE.

HCV Treatment forms in REDCap

Please remember to follow the criteria for completing HCV Treatment forms in REDCap:

• For patients enrolled in cohort 10, the HCV Treatment form should be completed if HCV treatment was ongoing during enrolment or has commenced after enrolment (baseline).
• For patients enrolled in EuroSIDA before cohort 10, the HCV Treatment form should be completed if HCV treatment was ongoing 1 June 2014 or has commenced after 1 June 2014.



PUBLICATIONS

Total number of publications in 2016: 11
Publications since last newsletter February 2016: 8

Tuberculosis-related mortality in people living with HIV In Europe and Latin America: an international cohort study. Daria Podlekareva, Anne Marie W. Efsen, Anna Schultze, Frank Post,, Alena M. Skrahina, Alexander Panteleev, Hansjakob Furrer, Robert F. Miller, Marcelo H. Losso, Javier Toibaro, Jose M. Miro, Anna Vassilenko, Enrico Girardi, Mathias Bruyans, Niels Obel, Jens D. Lundgren, Amanda Mocroft, Ole kirk on behalf of the TB:HIV study group in EuroCoord.
Lancet HIV. 2016 Mar;3(3):e120-31. doi: 10.1016/S2352-3018(15)00252-0. Epub 2016 Feb 2

Antiretroviral drugs and risk of chronic ALT elevation in HIV-infected persons without viral hepatitis coinfection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, F Dabis, A d'Arminio Monforte, C Smith, S de Wit, O Kirk, JD Lundgren, R Weber , on behalf of the D:A:D Study group.
Open Forum Infect Dis. 2016 Jan 21;3(1):ofw009. doi: 10.1093/ofid/ofw009. eCollection 2016.

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with human immunodeficiency virus (HIV)? A cohort collaboration. CA Sabin; P Reiss; L Ryom; AN Phillips, PhD; R Weber; M Law; E Fontas; A Mocroft; S de Wit; C Smith; F Dabis; A d'Arminio Monforte; W El-Sadr; JD Lundgren for the DAD study Group.
BMC Med. 2016 Mar 31;14(1):61. doi: 10.1186/s12916-016-0588-4.

Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals? DC Boettiger, CA Sabin, A Grulich, L Ryom, F Bonnet, P Reiss, A d'ArminioMonforte, O Kirk, A Phillips, M Bower, G Fätkenheuer, JD Lundgren, M Law on behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group
AIDS. 2016 Feb 5. [Epub ahead of print]

Improvements over time in short-term mortality following myocardial infarction in the D:A:D Study. CI Hatleberg, L Ryom, W El-Sadr, C Smith, P Weber, P Reiss, E Fontas, F Dabis, M Law, A d'Arminio

HCV Treatment Adverse Event forms in REDCap

The HCV Treatment Adverse Event form should be completed if HCV treatment is stopped early due to toxicity or intolerance.
Centres who deliver data in an electronic file should complete this form in REDCap for relevant patients.

Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosida.rigshospitalet@regionh.dk
No questions is too small or too big, we are happy to assist in all matters.

Saur, C Smith, R Weber, P Reiss, L Fontas, F Dabis, M Law, A d'Arminio Monforte, Stephane De Wit, A Mocroft, A Phillips, J D. Lundgren and C Sabin for the D:A:D Study Group
AIDS. 2016 Mar 4. [Epub ahead of print]

Infection-related and -unrelated malignancies, HIV and the aging population. Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A, on behalf of EuroSIDA in EuroCOORD.
HIV Med. 2016 Feb 18. doi: 10.1111/hiv.12359. [Epub ahead of print]

Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. DA Kamara, CA Sabin, L Ryom, P Reiss, M Rickenbach, CJ Smith, A Phillips, A Mocroft, S De Wit, M Law, A d'Arminio Monforte, F Dabis, C Pradier, JD Lundgren.
Antiviral Therapy, 2016

Associations between HIV-RNA-based indicators and virological and clinical outcomes. K Laut, L Shepherd, C Pedersen, JK Rockstroh, H Sambatakou, D Paduta, R Matulionyte, T Smiatacz, F Mulcahy, JD Lundgren, A Mocroft, O Kirk, on behalf of EuroSIDA in EuroCoord.
AIDS, 2016.

All publications may be found HERE

Thank you for a continuous rewarding and succesfull collaboration!

EuroSIDA Coordinating Centre. Rigshospitalet, University of Copenhagen. CHIP, Department of Infectious Diseases, Section 2100, Finsencentret. Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.
Tel: +45 35 45 57 57. Fax: +45 35 45 57 58. E-mail: EuroSIDA.rigshospitalet@regionh.dk
Web: www.regionh.dk www.chip.dk